Gaining prominence as a potential therapeutic option for primary Sjögren’s syndrome (pSS), belimumab is a monoclonal antibody specifically designed to target the B-cell activating factor (BAFF). This evidence concerns the gene TNFSF13B and peeling skin syndrome.